rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
|
30264293 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
First-generation BRAF inhibitors (BRAFi) have shown effectiveness in the treatment of melanoma patients with brain metastases and are currently undergoing clinical trials for the treatment of pediatric primary brain tumors with the BRAF-V600E mutation.
|
30265855 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
|
29310328 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical data on 283 patients with active BRAF V600E-mutant MBM treated with vemurafenib were provided by 70 US oncologists.
|
25991583 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, LDHA expression in human brain metastases was not associated with the number of tumors, BRAF(V600E) status, or survival.
|
25791837 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Silencing of PTEN in BRAF(V600E)/Cdkn2a(Null) melanomas cooperated with activated AKT1, resulting in decreased tumor latency and the development of lung and brain metastases in nearly 80% of tumor-bearing mice.
|
26565903 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
|
25073704 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We identified tissue samples of BM of gastro-oesophageal cancer and analyzed the expression of human epidermal growth factor receptor-2 (HER2), phosphorylated signal transducer and activator of transcription-3 (pSTAT3), epithelial growth factor receptor (EGFR), V600E point mutation of the v-raf murine sarcoma viral oncogene homolog-B1 (BRAF V600E), cluster of differentiation molecule-34 (CD34), hypoxia inducible factor-1α (HIF 1-α) and Ki-67 by immunohistochemical methods.
|
23482783 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, expression of BRAF V600E mutant protein occurs in approximately 6% of BM and is consistent in different tumor manifestations of the same patient.
|
22012135 |
2012 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib has activity and an acceptable safety profile in patients with Val600Glu BRAF-mutant melanoma and brain metastases irrespective of whether they are untreated or have been previously treated but have progressed.
|
23051966 |
2012 |